Modality
Peptide
MOA
CD3xCD20
Target
PARP
Pathway
Hedgehog
LNOvarian CaAS
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
Aug 2020
→ Nov 2026
Phase 2Current
NCT07454432
2,047 pts·Ovarian Ca
2020-08→2026-11·Terminated
2,047 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-208mo awayPh2 Data· Ovarian Ca
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2026-11-20 · 8mo away
Ovarian Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07454432 | Phase 2 | Ovarian Ca | Terminated | 2047 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |